ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Kris Bryant “running out of time” to return to Rockies this season – The Cannabist

Kris Bryant, who has struggled with injuries throughout his unproductive, three-year tenure with the Rockies, could be done for the season as he continues dealing

September 8, 2024

New Firearm Injury Numbers; Another Indication for Semaglutide?

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange,

August 4, 2024

MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World’s First Take-Home Microdosing Study in Patients with Depression | Psychedelic Invest

This trial is a world first and remains the only clinical trial in the world to be approved for take-home use of LSD. MB22001 is

August 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.